Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MET | P08581 | 3/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.33 |
| ▸ | SYK | P43405 | 5/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1701327 | 0.74 | ADRA1A (0.34) | METGRM4SYKADRA1AADRA2A | |
| SCHEMBL12223458 | 0.72 | MAPK1 (0.50) | MAPK1 | |
| SCHEMBL12146875 | 0.72 | HTR2A (0.41) | MET | |
| SCHEMBL4878480 | 0.69 | MAPK1 (0.56) | MAPK1ADRA2AADRA2C | |
| SCHEMBL12244242 | 0.68 | MAPK1 (0.50) | MAPK1MET | |
| SCHEMBL12605459 | 0.67 | POLB (0.43) | MAPK1ALOX15HTTGLO1 | |
| SCHEMBL2354692 | 0.66 | MAPK1 (0.43) | MAPK1SYK | |
| SCHEMBL1093217 | 0.66 | RPS6KA5 (0.40) | METADRA1A | |
| SCHEMBL7738688 | 0.65 | MAPK1 (0.52) | MAPK1ADRA2AADRA2C | |
| SCHEMBL12146874 | 0.65 | CYP2C19 (0.42) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119637-B2 | Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8110576-B2 | Pyrrolo(2,3-b)pyrazine compounds; Raf kinase inhibitors including A-Raf, B-Raf and/or c-Raf-1 oncogenes; melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease | PLEXXIKON INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306087-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, PRKACA, RAF1 | MAPK1 79/4885MET 201/4885GRM4 3428/4885 |
| US-20090306086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PRKACA, KIT, FLT3 | MAPK1 143/4885MET 359/4885GRM4 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.